Contracts › 75A50120C00169
75A50120C00169: Clinical Development of Crispr-CAS3 Phage Cocktail for the Treatment of Recurrent Urinary Tract Infections Caused By Escherichia Coli Including Antimicrobial and Multi-Drug Resistant Strains
Awarded to Locus Biosciences Inc by Office of Assistant Secretary for Preparedness and Response.
$73.9Mobligated
$109.8Mpotential value
31 December 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50120C00169 |
|---|---|
| Awardee | Locus Biosciences Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | NC |
| Offers received | 1 |
| Period of performance | 28 September 2020 to 31 December 2026 |
| Potential end | 01 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record